TGF-β has been shown to downregulate the expression of the activating receptor NKG2D in CD8+ T cells and NK cells; silencing of TGF-β in glioma cells promotes their recognition by CD8+ T cells and NK cells [119,120]. This evidence concerns the gene CD8A and central nervous system cancer.